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Background: The aim of this single-arm phase II study was to
evaluate the efficacy, feasibility, and safety of the gemcitabine-
carboplatin-paclitaxel combination as neoadjuvant chemotherapy in
patients with operable non-small cell lung cancer (NSCLC).
Methods: Patients with stage IB, II, or IIIA NSCLC were given
three cycles of chemotherapy followed by tumor resection. Each
21-day cycle consisted of gemcitabine 1000 mg/m2 on days 1 and 8,
carboplatin AUC 5 on day 1, and paclitaxel 175 mg/m2 on day 1.
Results: Forty-four patients were enrolled: 18.2% of patients had
stage IB, 15.9% had stage II, and 65.9% had stage IIIA NSCLC. All
patients received three cycles of treatment. The clinical tumor
response rate was 76.2% (32 of 42 patients; 95% CI, 60.5–87.9%).
Thirty-six patients had a complete tumor resection, five of whom
had a complete pathological response with no viable tumor cells in
the resected tumor on histological examination. Median time to
progression was 13.6 months (95% CI, 8.9, 16 months), and 26 of
44 patients (59.1%) had progressed. The 1-year disease-free survival
rate was 53.6% (95% CI, 38.7–68.5%), and the 1-year survival rate
was 86.0% (95% CI, 75.7–96.4%). Grade 3 and 4 neutropenia each
occurred in 38.6% of patients, and grade 3 infection occurred in
2.3% of patients; grade 3 and 4 thrombocytopenia occurred in 25.0%
and 0% of patients, respectively.
Conclusion: The gemcitabine-carboplatin-paclitaxel combination
showed promising efficacy and seemed to be safe and feasible as
neoadjuvant chemotherapy in patients with operable-stage NSCLC.
Key Words: Non-small cell lung cancer, Neoadjuvant chemother-
apy, Triplet regimen.
(J Thorac Oncol. 2006;1: 135–140)
Non-small cell lung cancer (NSCLC) is the most commonmalignancy worldwide; it is the most common cause of
cancer death in men and among the leading causes of cancer
death in women.1,2 Approximately 40% of patients with
NSCLC present with stage IB through IIIA disease. These
patients may be considered candidates for surgery; however,
long-term survival for patients with stage IB through IIIA
NSCLC after tumor resection is only 9 to 38%, depending on
the stage of disease.3 This disappointing survival rate is most
often the result of the presence of micrometastases at the time
of tumor resection.
A series of recent studies have demonstrated a relative
survival benefit of 14% or more with platinum-based adju-
vant chemotherapy after resection for NSCLC,4,5 and adju-
vant chemotherapy has been widely adopted as standard
practice. Chemotherapy before surgery may be preferable to
adjuvant chemotherapy as it will be better tolerated, and, in
addition to eradicating micrometastases, it may reduce the
local tumor burden, facilitating tumor resection. Randomized
phase III trials have suggested that chemotherapy before
surgery may improve survival in patients with operable
NSCLC.6–10 These studies used older platinum combinations;
with the advent of newer cytotoxic agents such as paclitaxel,
docetaxel, and gemcitabine, doublets containing these agents
in combination with cisplatin or carboplatin have been tested
in the neoadjuvant setting in phase II trials with promising
results.11–16
One approach to improve the efficacy of neoadjuvant
chemotherapy is to add a third agent with a different mech-
anism of action and mostly non-overlapping toxicity. In
patients with advanced, inoperable NSCLC, three-drug regi-
mens have been found to have higher activity compared with
doublet regimens, but this was accompanied by higher tox-
icity and no increase in survival.17 However, it is likely that
patients with less advanced NSCLC would be able to tolerate
a more intensive chemotherapy regimen. Because the aim of
neoadjuvant chemotherapy is to increase the cure rate, the
role of a safe and convenient triplet regimen merits consid-
eration in this setting. Triplet combinations containing gem-
citabine, paclitaxel, and cisplatin or carboplatin have been
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found to be both safe and effective in advanced NSCLC.18–22
Two studies have shown that the gemcitabine-cisplatin-pac-
litaxel combination also has significant activity as neoadju-
vant chemotherapy in patients with stage IIIA (N2) and IIIB
NSCLC, with clinical response rates of 71% and 73.5%,
pathological complete response rates of 7% and 16.3%, and
1-year survival rates of 92% and 85%.23,24 In both of these
studies, chemotherapy was well tolerated, which indicates
that a triplet regimen is a feasible approach for neoadjuvant
chemotherapy.
The concept of neoadjuvant chemotherapy therefore
seems to be promising for patients with resectable NSCLC,
and further exploration of new drugs and regimens in this
setting is warranted. The aim of this study was to evaluate the
efficacy, feasibility, and safety of the gemcitabine-carbopla-
tin-paclitaxel (GCP) triplet regimen when used as neoadju-
vant chemotherapy in patients with operable early-stage
NSCLC.
MATERIALS AND METHODS
Patients eligible for this study (B9E-MC-S179) had a
histologic or cytologic diagnosis of NSCLC of any subtype;
stage IB, II, or IIIA disease; tumor amenable to curative
surgical resection; and bidimensionally measurable disease.
No prior tumor therapy was allowed. Other inclusion criteria
included Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 or 1; age of at least 18 years and no older
than 65 years; white blood cell count 3.5  109/liter;
absolute neutrophil count (ANC) 1.5  109/liter; platelets
100  109/liter; hemoglobin 9.0 g/dL; serum bilirubin
1.0  upper limit of normal (ULN); alanine aminotrans-
ferase (ALT) or aspartate aminotransferase (AST) 2.5 
ULN; alkaline phosphatase 1.0  ULN; serum creatinine
1.5  ULN; and calculated creatinine clearance 40 mL/
min. Exclusion criteria included concurrent administration of
any other tumor therapy; pregnancy or breast feeding; active
infection; poorly controlled diabetes mellitus; a second pri-
mary malignancy clinically detectable at the time of enroll-
ment; peripheral neuropathy of Common Toxicity Criteria
(CTC) grade 2; and history of hypersensitivity to drugs
formulated in Cremophor EL, the vehicle used for commer-
cial paclitaxel formulations. The study was conducted ac-
cording to ICH Good Clinical Practice Guidelines, including
obtaining written informed consent from all patients.
Before study enrollment, patients were required to have
a physical examination, chest radiograph, computed tomog-
raphy (CT) scan of the thorax, and complete blood work-up.
A physical examination and full blood work-up were per-
formed before the start of each cycle, and a full blood count
was obtained within 1 day before the day 8 dosing of
gemcitabine and between days 14 to 16 of each cycle.
Three cycles of chemotherapy were planned, followed
by tumor resection. Gemcitabine was administered via intra-
venous infusion over approximately 30 to 60 minutes at 1000
mg/m2 on days 1 and 8 of each 21-day cycle. Carboplatin was
given as an intravenous infusion over approximately 30 to 60
minutes at a dose of AUC 5 mg/mL  minute on day 1 of
each cycle. The Calvert formula was used to calculate the
carboplatin dose.25 Paclitaxel was administered via intrave-
nous infusion over approximately 3 hours at a dose of 175
mg/m2 on day 1 of each cycle. The sequence of drug admin-
istration on day 1 was paclitaxel followed by gemcitabine and
then carboplatin. Patients received intravenous premedication
with dexamethasone 20 mg, diphenhydramine 50 mg (or
another antihistamine of comparable strength that is routinely
used in local practice), and cimetidine 300 mg (or ranitidine
50 mg) administered approximately 30 minutes before the
start of the paclitaxel infusion.
To start the next cycle, ANC had to be1.5 109/liter
and platelets 100  109/liter. Dose adjustments for hema-
tologic toxicity at the start of a cycle of treatment were based
on the nadir neutrophil and platelet counts from the preceding
cycle. Treatment could be delayed for up to 35 days from day
1 of the current cycle. The doses of gemcitabine, carboplatin,
and paclitaxel were reduced by 20% in the case of: platelets
25  109/liter without bleeding and ANC 0.5-0.99 
109/liter without fever or infection; platelets 25  109/liter
without bleeding and ANC 0.5  109/liter; platelets 25-
49.9  109/liter with bleeding; and platelets 25  109/liter.
Any patient who required a dose adjustment based on nadir
hematology values received the reduced dose for the remain-
der of the study. Dose adjustments on day 8 were based on
the day 8 hematology values and had no effect on dosing in
the subsequent cycles. If dose adjustment was required for
non-hematologic toxicity, the patient received the reduced
dose for the remainder of the study; dose re-escalation was
not permitted. In the event of peripheral neuropathy of CTC
grade 2, subsequent doses of paclitaxel were reduced by 20%;
in the event of CTC grade 3 or 4 toxicity, therapy was
discontinued. In the event of myalgia, arthralgia, asthenia, or
fatigue of CTC grade 2 lasting more than 7 days, subsequent
doses of gemcitabine and paclitaxel (but not carboplatin)
were reduced by 20%; in the event of CTC grade 3 or 4
toxicity, therapy was discontinued. In the event of hypersen-
sitivity reaction of CTC grade 1 or 2, discontinuation of
paclitaxel treatment was at the investigator’s discretion,
based on tumor response and the investigator’s medical
judgment. If paclitaxel treatment continued, the dose was not
reduced; if paclitaxel treatment was discontinued, the gem-
citabine and carboplatin doses were not reduced.
A plain chest radiograph was performed between days
15 and 22 of cycle 2 of chemotherapy or whenever clinically
indicated to exclude tumor progression. If the chest radio-
graph suggested tumor progression, then a CT thorax scan
was performed. A CT thorax scan was performed between
days 15 and 22 of cycle 3 for tumor measurement and
preoperative tumor assessment. After completion of the three
planned cycles of chemotherapy, patients were assessed for
medical fitness for surgery. Patients who no longer qualified
for surgery received radiation therapy, either radical or pal-
liative, as clinically indicated. Patients who qualified for
surgery underwent tumor resection between days 29 and 36
of the final cycle of chemotherapy. After surgery (or radical
radiotherapy if the patient was medically unfit for surgery),
patients had tumor assessments approximately every 2
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months until 12 months after surgery (or start of radiother-
apy), tumor recurrence, or death, whichever occurred first.
This study had only a single planned clinical tumor
response assessment before surgery. Patients qualified for a
best clinical response of complete response (CR), partial
response (PR), or stable disease (SD) according to the clinical
response criteria (specified below) documented at this single
tumor assessment. Patients with an objective status of pro-
gressive disease (PD) on the first on-study tumor assessment
had a best clinical response of PD. CR was defined as
complete disappearance of all measurable and evaluable dis-
ease; PR as at least a 50% reduction in the sum of products of
perpendicular diameters of all measurable lesions; PD as an
increase equal to or greater than 25% in the sum of products
of all bidimensionally measurable lesions, or clear worsening
of any evaluable disease, or reappearance of any lesion that
had disappeared, or appearance of any new lesion/site, or
failure to return for evaluation due to death, or deteriorating
condition (unless clearly unrelated to this cancer); and SD
was defined as any response not qualifying for CR, PR, or
PD. Time to treatment failure and time to documented disease
progression were measured from the date of study enrollment
to the date of disease progression, death, or, for treatment
failure only, the date of early discontinuation of therapy.
Survival time was calculated from the date of enrollment to
the date of death from any cause. All analyses were censored
at the date of last follow-up visit for patients who had not
experienced the relevant events and used the Kaplan-Meier
method. Assessments continued until death or 12 months
after surgery (or first dose of radiotherapy), whichever oc-
curred first. Toxicity was graded according to the National
Cancer Institute Common Toxicity Criteria, version 2.0.26
Statistical analysis was conducted using SAS v8.2.
The clinical tumor response rate was defined as the
number of patients with documented PR or CR divided by the
number of patients who qualified for tumor response analysis.
Pathological CR was defined as the absence of any viable
tumor cells in resected tumor specimens on histological
examination, including primary tumor and lymph nodes. The
pathological CR rate was defined as the number of patients
with documented histological complete response divided by
the number of patients who qualified for analysis of patho-
logical complete response. The complete tumor resection rate
was defined as the number of patients with complete tumor
resection divided by the number of patients who were en-
rolled in the study and met the eligibility criteria.
The primary objective of this study was to evaluate the
clinical response rate to neoadjuvant chemotherapy with the
GCP combination in patients with operable early-stage
NSCLC. The secondary objectives included safety, the patho-
logical CR rate, the complete tumor resection rate after
chemotherapy, time-to-event measures, and overall survival.
The sample size calculation was based on the hypoth-
esis that the true clinical response rate would be 80% and that
a low clinical response rate would be 60%. Fifty patients
provided 87% power to detect an improvement in clinical
response rate from 60 to 80%.
RESULTS
Forty-four patients were enrolled in this study. Two
patients did not qualify for the efficacy analyses: one patient
received 5-fluorouracil and leucovirin at the beginning of
cycle 2, and one patient was discovered to have had brain
metastases at baseline and therefore did not meet the protocol
criteria. The baseline characteristics of the study population
are shown in Table 1. Approximately two thirds of the
patients had stage IIIA disease.
All 44 patients received three cycles of chemotherapy.
In the 42 patients eligible for efficacy analysis, 32 patients
had a PR to the GCP combination, for a clinical tumor
response rate of 76.2% (95% CI, 60.5–87.9%). Seven pa-
tients (16.7%) had SD (95% CI, 7.0–31.4%), and three
patients (7.1%) had PD (95% CI, 1.5–19.5%). When exam-
ined according to disease stage, the clinical tumor response
rate was 66.7% (95% CI, 38.4–88.2%) among the patients
with stage IB and II disease (n  10) and 81.5% (95% CI,
61.9–93.7%) among the patients with stage IIIA disease (n
22).
After chemotherapy, three patients did not qualify for
surgery: the patient with brain metastases (the same patient
who was excluded from the efficacy analyses); one patient
who died from the study disease; and one patient whose
tumor was no longer amenable to surgery. Of the 41 patients
who qualified for surgery, 36 patients had a complete tumor
resection, five of whom had a pathological CR with no viable
tumor cells in the resected tumor on histologic examination.
The pathological CR rate was 12.2% (5 of 41 patients), and
the complete tumor resection rate was 81.8% (36 of 44
patients). Of the patients who underwent surgery, the resec-
tion rate was 87.8% (36 of 41 patients).
Follow-up data to approximately 15 months were ob-
tained, by which time the median time to progression had
been obtained. Median time to progression, median time to
treatment failure, and median disease-free survival were 13.6
TABLE 1. Baseline Patient Characteristics
Characteristic n  44
Sex
M 39 (88.6%)
F 5 (11.4%)
Age (yr) (mean  SD) 56.4  7.3
Age (range) 37–67
Origin
Caucasian 8 (18.2%)
East/Southeast Asian 33 (75.0%)
Other 3 (6.8%)
Disease stage
IB 8 (18.2%)
II 7 (15.9%)
IIIA 29 (65.9%)
ECOG status
0 23 (52.3%)
1 21 (47.7%)
ECOG, Eastern Cooperative Oncology Group.
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months (95% CI, 8.9, 16 months). The Kaplan-Meier
curves of time to progression and overall survival time are
shown in Figures 1 and 2. The 1-year disease-free survival
rate was 53.6% (95% CI, 38.7–68.5%), and the 1-year
survival rate was 86.0% (95% CI, 75.7–96.4%). Of the 44
patients, 26 (59.1%) had progressed.
Grade 3/4 hematological toxicity was reported in 37
patients (84.1%), and non-hematological toxicity was re-
ported in 10 patients (22.7%). Individual grade 3/4 toxicities
are listed in Table 2. The most common grade 3/4 toxicities
reported were neutropenia (grade 3, 17 patients, 38.6%; grade
4, 17 patients, 38.6%) and thrombocytopenia (grade 3, 11
patients, 25.0%). Clinical complications of hematological
toxicity were rare. One patient (2.3%) experienced grade 3
infection. There were no drug-related deaths. Six patients
required a transfusion: four patients had a red blood cell
transfusion, one patient had a platelet transfusion, and one
patient had a whole-blood transfusion.
Dose delays and reductions are shown in Table 3. The
day 1 dose of gemcitabine was delayed or reduced in 14
cycles (10.6%), and the day 8 dose was delayed or reduced in
54 cycles (40.9%). The carboplatin and paclitaxel doses were
delayed or reduced in 15 cycles (11.4%) and 14 cycles
(10.6%), respectively.
DISCUSSION
Most patients with NSCLC who are candidates for
surgery already have systemic micrometastases so that, de-
spite tumor resection, the long-term survival rates in these
patients are poor. The main aim of neoadjuvant chemother-
apy in operable NSCLC is to improve the cure rate; it is
therefore important to investigate the activity of different
drug combinations, including more intensive regimens.
In the present study, the triplet combination of GCP
showed promising efficacy as neoadjuvant chemotherapy in
patients with operable stage IB, II, and IIIA NSCLC, with a
CR rate of 76.2%, a complete resection rate of 81.8%, a
pathologic CR rate of 12.2%, and a 1-year survival rate of
86.0%.
Neoadjuvant chemotherapy consisting of two cycles of
paclitaxel-carboplatin was studied by the Bimodality Lung
Oncology Team in patients with a negative mediastinoscopy
before treatment (largely stage I and II disease) and resulted
in an objective response rate of 56% and a complete resection
rate of 86%.27 This prompted an Intergroup phase III study
(SWOG 9900) of neoadjuvant chemotherapy compared with
surgery alone.28 This study was, however, closed after adju-
vant chemotherapy became accepted as the standard of care.
In other studies of doublet regimens, the response rates
to chemotherapy ranged from 40 to 70%, the complete
resection rate was generally greater than 70% (although two
exceptional studies had rates of 17% and 55%), and the
pathologic CR ranged from 2 to 16% (Table 4).11–16 Median
survival in these studies ranged from 14.5 to 27.6 months,
and the 1-year survival rates ranged from 67 to 85%.
The triplet combination of gemcitabine-cisplatin-pacli-
taxel as neoadjuvant chemotherapy resulted in clinical re-
sponse rates of 71% and 73.5%, pathological complete re-
FIGURE 1. Time to progression.
FIGURE 2. Overall survival.
TABLE 2. Toxicities
Toxicity Grade 3 Grade 4
Hematological
Neutropenia 17 (38.6) 17 (38.6%)
Thrombocytopenia 11 (25.0) 0
Anemia 4 (9.1) 0
Febrile neutropenia 1 (2.3) 0
Bleeding 1 (2.3) 0
Infections
Infection 1 (2.3) 0
Non-hematological
Vomiting 1 (2.3) 0
Drug hypersensitivity 1 (2.3) 0
Rash 1 (2.3) 0
Alanine aminotransferase 3 (6.8) 0
Values are presented as n (%). n  44.
TABLE 3. Dose Delays and Reductions
Drug Delayed Reduced Delayed or reduced
Gemcitabine (day 1) 9 (6.8) 8 (6.1) 14 (10.6)
Gemcitabine (day 8) 2 (1.5) 53 (40.2) 54 (40.9)
Carboplatin 10 (7.6) 9 (6.8) 15 (11.4)
Paclitaxel 9 (6.8) 8 (6.1) 14 (10.6)
Values are expressed as n (%). The total number of possible administrations was
132 for each drug each day.
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sponse rates of 7 and 16.3%, and 1-year survival rates of 92%
and 85% in two separate studies.23,24 In both of these studies,
the chemotherapy was well tolerated, which indicates that a
triplet regimen is a feasible approach for neoadjuvant che-
motherapy. These results are similar to those in the current
study. Among patients with advanced disease, a recent meta-
analysis of abstracted data found a survival advantage with
the use of cisplatin compared with carboplatin when the
agents were combined with other new agents.29 It is un-
known, however, whether these findings would also apply to
triplet therapy. The treatment-related deaths were similar
with cisplatin and carboplatin. The use of cisplatin was
associated with significantly more nausea and vomiting; the
use of carboplatin was associated with more thrombocytope-
nia, but this was not clinically significant.29 In adjuvant
studies of chemotherapy after resection, both cisplatin and
carboplatin resulted in an improvement of survival rates.5
The response rates observed with these gemcitabine-
platinum-paclitaxel triplet combinations as neoadjuvant che-
motherapy (23,24, and current study) are higher than those
reported for doublet regimens, which supports the notion that
triplet combinations produce higher response rates than dou-
blet combinations (Table 4).11–16 In addition, the resection
rates, complete pathologic response rates, and 1-year survival
rates in response to the triplet regimens were at the high end
of, or above, the ranges reported for the doublet regimens,
which indicates that gemcitabine-platinum-paclitaxel combi-
nations have significant activity as neoadjuvant chemother-
apy.
The addition of a third drug has the potential risk of
increasing toxicity. In the treatment of advanced NSCLC,
doublet chemotherapy is preferred over triplet regimens be-
cause it causes less toxicity.17 However, patients with earlier
stage NSCLC before surgery would most likely have a better
performance status and be better able to tolerate toxicity. In
addition, the total number of cycles is limited to not more
than three in neoadjuvant chemotherapy, whereas four cycles
of chemotherapy are commonly given in patients with more
advanced disease.30 In the studies of gemcitabine-cisplatin-
paclitaxel,23,24 the toxicity was mainly hematological in na-
ture, with grade 3 and 4 neutropenia reported in 28% and
32.7% of patients and grade 3 and 4 thrombocytopenia
reported in 11% and 12.2% of patients. The rates of grade 3
and 4 neutropenia (38.6% and 38.6%) and thrombocytopenia
(25% and 0%) were not markedly different in the present
study with carboplatin at an AUC of 5, although carboplatin
causes greater myelosuppression than cisplatin.31,32 The GCP
combination was well tolerated in this study, with all patients
able to receive the planned three cycles of chemotherapy, an
infection rate of 2.3%, and no drug-related deaths.
In conclusion, the GCP combination showed promising
efficacy in this largely stage IIIA population and seems to be
safe and feasible as neoadjuvant chemotherapy in patients
with operable stage NSCLC. Adjuvant chemotherapy after
surgical resection has become standard practice. Neoadjuvant
chemotherapy before surgery may be expected to have a more
favorable outcome because of better patient tolerance and the
early treatment of micrometastases. In the neoadjuvant set-
ting, triplet chemotherapy merits comparison in a randomized
phase III study with doublet chemotherapy regimens.
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TABLE 4. Neoadjuvant Chemotherapy Regimens in NSCLC
Reference Stage
Chemotherapy
regimen
Response
rate
Resection
ratea
Pathologic complete
response rateb
Doublet combinations
Pisters et al.27,c Stage I, II, IIIA Pac/carb 56% 92%
van Zandwijk et al.11,d Stage IIIA N2 Gem/cis 70% 71%
Santo et al.12 Stage IIIA N2 and IIIB Gem/cis 60% 81%
Migliorino et al.13 Stage IIIA N2 and IIIB Gem/cis 57% 93% 3%
Betticher et al.14 Stage III N2 Doc/cis 66% 55% 16%
Cappuzzo et al.15 Stage IIIA-bulky N2 and stage IIIB Gem/cis 62% 95% 2%
O’Brien et al.16 Stage IIIA N2 Pac/carb 64% 17%
Pisters et al.28 T2N0, T1-2N1, and T3N0-1 Pac/carb 40%
Triplet combinations
Roth et al.6 Stage IIIA Cyc/etop/cis 35%
Rosell et al.8 Stage IIIA Mit/ifos/cis 60% 85% 3%
Depierre et al.10 Stage I (except T1N0), II and IIIA Mit/ifos/cis 64% 92%
Cappuzzo et al.23 Stage IIIA N2 and IIIB Gem/cis/pac 71% 76% 7%
De Marinis et al.24 Stage IIIA(N2) Gem/cis/pac 73.5% 100% 16%
Carb, carboplatin; Cis, cisplatin; Cyc, cyclophosphamide; Doc, docetaxel; Etop, etoposide; Gem, gemcitabine; Ifos, ifosfamide; Mit, mitomycin; NSCLC, non–small cell lung
cancer; Pac, paclitaxel.
aResection rate of patients who underwent surgery.
bPathologic complete response rate of patients who started the study.
cA negative mediastinoscopy was required.
dAfter chemotherapy, patients were randomized to surgery or radiotherapy.
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